Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Regimen Clear all

Conditions: Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Interventions: Avelumab, Oxaliplatin, 5-Fluorouracil, Leucovorin, Capecitabine, Best supportive care; Drug · Other
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 35
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more

Conditions: Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
Interventions: PCI-27483, Gemcitabine; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • Anaheim, California • Titusville, Florida + 13 more

Conditions: Relapse Remitting Multiple Sclerosis
Interventions: Ofatumumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 35
States / cities: Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Thrombotic Microangiopathy
Interventions: Ravulizumab, Placebo, Best supportive care; Biological · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Tampa, Florida • Grosse Pointe Farms, Michigan • Durham, North Carolina + 2 more

Conditions: Sun-Damaged Skin, Retinoid Intolerance
Interventions: Tazorac, Dove Mild Cleanser, Dove Facial Moisturizer; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Medication Adherence
Interventions: Nurse Coach Intervention; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Hyperlipidemia
Interventions: Standard Process 21 Day Purification Program (SPPP); Other
Lead sponsor: Logan College of Chiropractic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Hypertension
Interventions: High Intensity Intervention, Low Intensity Intervention, All- 6 month pharmacist intervention; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pituitary Tumor, Pain
Interventions: IV Caldolor, IV Placebo; Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 79 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Atopic Dermatitis, Eczema
Interventions: Pre-Treatment with Dial liquid antibacterial soap, Control; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Sensorineural Hearing Loss
Interventions: LY3056480; Drug
Lead sponsor: Audion Therapeutics BV; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Norfolk, Virginia

Conditions: Mycobacterium Infections, Nontuberculous
Interventions: ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS); Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 90
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more

Conditions: Staining
Interventions: whitening maintenance, whitening maintenance MW, negative control; Other
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: HIV-1 Infection
Interventions: Vesatolimod, Placebo, ART; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Ft. Pierce, Florida + 3 more

Conditions: Graves' Ophthalmopathy (GO)
Interventions: RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection); Drug · Other
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more

Conditions: Postoperative Pain, Narcotic Use, Analgesia, Endocrine Surgery, Opioid Use, Opioid Abuse
Interventions: POINT; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Plaque Psoriasis
Interventions: ORKA-001, Placebo; Drug · Other
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Los Angeles, California + 15 more

Conditions: Influenza
Interventions: Placebo, Favipiravir; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions: GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate; Biological · Procedure · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: Obatoclax, Carboplatin/etoposide; Drug
Lead sponsor: Gemin X; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 27 more

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: 4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • Escondido, California • Atlanta, Georgia + 1 more

Conditions: HIV Infections, Depression
Interventions: Directly Observed Therapy (DOT), Fluoxetine; Behavioral · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psilocybin
Interventions: Psilocybin, Midazolam, Saline; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance

Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence

Standard Process 21 Day Purification Program Project

Trial of Low and High Intensity Strategies to Maintain BP Control

Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

A Trial of LY3056480 in Patients With SNLH

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Clinical Study to Assess the Efficacy of Professional Tooth Whitening Maintenance System

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Postoperative Opt-In Narcotic Treatment Study

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

GVAX vs. Placebo for MDS/AML After Allo HSCT

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles

Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy

The RECAP2 Study: Midazolam and Psilocybin